We are live on ! Find out more
SURF

Surface Oncology, Inc. Common Stock
SURF

Delisted

SURF was delisted on the 7th of September, 2023.

Back to rankings

91 hedge funds and large institutions have $213M invested in Surface Oncology, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

320% more first-time investments, than exits

New positions opened: 42 | Existing positions closed: 10

54% more funds holding

Funds holding: 59 → 91 (+32)

44% more capital invested

Capital invested by funds: $149M → $213M (+$64.8M)

33% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 18

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

41% less call options, than puts

Call options by funds: $1.3M | Put options by funds: $2.2M

Holders
91
Holders Change
+32
Holders Change %
+54.24%
% of All Funds
1.61%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
42
Increased
24
Reduced
18
Closed
10
Calls
$1.3M
Puts
$2.2M
Net Calls
-$895K
Net Calls Change
-$1.03M

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$18.2M
2
FCM
Farallon Capital Management
California
+$8.69M
3
Morgan Stanley
Morgan Stanley
New York
+$8.57M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.97M
5
BlackRock
BlackRock
New York
+$5.75M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$28.5M
2
VA
VR Adviser
New York
-$21.2M
3
AVAI
Atlas Venture Associates IX
Massachusetts
-$14.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$12.1M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
AVAI
1
Atlas Venture Associates IX
Massachusetts
$27.2M -$14.8M -1,700,000 -37%
AVAX
2
Atlas Venture Associates XI
Massachusetts
$27.2M +$25.6M +2,945,453 New
AIM
3
ARK Investment Management
Florida
$23.5M +$18.2M +2,088,322 +460%
VA
4
VR Adviser
New York
$13.3M -$21.2M -2,435,000 -63%
Morgan Stanley
5
Morgan Stanley
New York
$9.92M +$8.57M +986,495 +1,139%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$9.45M +$5.97M +686,900 +205%
Vanguard Group
7
Vanguard Group
Pennsylvania
$9.34M +$1.15M +132,626 +15%
GTC
8
Ghost Tree Capital
New York
$9.24M – – –
FCM
9
Farallon Capital Management
California
$9.24M +$8.69M +1,000,000 New
ACP
10
Acuta Capital Partners
California
$9.23M -$769K -88,500 -8%
BlackRock
11
BlackRock
New York
$8.8M +$5.75M +661,807 +228%
CC
12
Commodore Capital
New York
$4.32M +$4.07M +467,796 New
Acadian Asset Management
13
Acadian Asset Management
Massachusetts
$3.84M +$190K +21,863 +6%
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$3.83M -$12.1M -1,389,020 -77%
Victory Capital Management
15
Victory Capital Management
Texas
$3.48M -$573K -65,980 -15%
Macquarie Group
16
Macquarie Group
Australia
$3.23M +$3.04M +350,000 New
Deutsche Bank
17
Deutsche Bank
Germany
$2.86M +$2.67M +307,459 +17,970%
Verition Fund Management
18
Verition Fund Management
Connecticut
$2.72M +$573K +65,916 +29%
Grantham, Mayo, Van Otterloo & Co (GMO)
19
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$2.33M +$2.19M +252,000 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$1.87M +$1.76M +202,805 New
Two Sigma Advisers
21
Two Sigma Advisers
New York
$1.86M -$817K -94,000 -32%
DLPIC
22
Davide Leone & Partners Investment Company
United Kingdom
$1.77M +$1.66M +191,128 New
Millennium Management
23
Millennium Management
New York
$1.76M +$1.66M +191,035 New
CCM
24
CAAS Capital Management
New York
$1.75M +$1.65M +189,781 New
PHP
25
Parkman Healthcare Partners
Connecticut
$1.62M -$211K -24,227 -12%
1
2 3 4 5

SURF Hedge Fund Activity: Q4 2020 in Review

91 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q4 2020, worth a combined $213M — up 44% from $149M a quarter earlier.

Buyers outnumbered sellers: 42 funds opened new SURF positions and 10 closed out — a net gain of 32 holders — while 24 added to existing stakes and 18 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $18.2M. The largest seller was EcoR1 Capital, cutting an estimated $28.5M.

  • 91 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q4 2020, up from 59 in Q3 2020.
  • Funds reported $213M of Surface Oncology, Inc. Common Stock stock for Q4 2020, up 44% quarter-over-quarter.
  • 42 funds opened new Surface Oncology, Inc. Common Stock positions in Q4 2020 and 10 closed out, a net change of +32 holders.
  • The largest Surface Oncology, Inc. Common Stock buyer in Q4 2020 was ARK Investment Management, an estimated $18.2M added.
  • The largest Surface Oncology, Inc. Common Stock seller in Q4 2020 was EcoR1 Capital, an estimated $28.5M sold.

Based on aggregated 13F filings for Q4 2020.